To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05877430
Title Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors CJ Bioscience, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California, Irvine RECRUITING Irvine California 92697 United States Details
University of Pittsburgh RECRUITING Pittsburgh Pennsylvania 15260 United States Details
Samsung Medical Center RECRUITING Seoul Korea, Republic of Details
Severance Hospital RECRUITING Seoul Korea, Republic of Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field